Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too
Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too
Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too
Submitted by
admin
on May 5, 2014 - 10:22am
Source:
Fierce Pharma
News Tags:
earnings
M&A
Pfizer
AstraZeneca
Headline:
Pfizer's 'weak' Q1 numbers bolster case for AZ buy--and post-merger split, too
Do Not Allow Advertisers to Use My Personal information
